Kevin Melody
Overview
Explore the profile of Kevin Melody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woolsey C, Borisevich V, Prasad A, Agans K, Deer D, Dobias N, et al.
Nat Immunol
. 2020 Nov;
22(1):86-98.
PMID: 33235385
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to screen...
2.
Cross R, Bornholdt Z, Prasad A, Geisbert J, Borisevich V, Agans K, et al.
Nat Commun
. 2020 Jul;
11(1):3736.
PMID: 32719371
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against...
3.
Woolsey C, Borisevich V, Prasad A, Agans K, Deer D, Dobias N, et al.
bioRxiv
. 2020 Jun;
PMID: 32511377
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to screen...
4.
Agarwal Y, Beatty C, Biradar S, Castronova I, Ho S, Melody K, et al.
Retrovirology
. 2020 Apr;
17(1):8.
PMID: 32276640
The development of safe and effective combination antiretroviral therapies for human immunodeficiency virus (HIV) infection over the past several decades has significantly reduced HIV-associated morbidity and mortality. Additionally, antiretroviral drugs...
5.
Melody K, Roy C, Kline C, Cottrell M, Evans D, Shutt K, et al.
J Virol
. 2020 Jan;
94(8).
PMID: 31969438
As a long-acting formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has been proposed for use as preexposure prophylaxis (PrEP) and the prevalence of transmitted RPV-resistant viruses can...
6.
Boyer P, Melody K, Smith S, Dunn L, Kline C, Fischer D, et al.
J Virol
. 2019 Mar;
93(11).
PMID: 30894467
Two mutations, G112D and M230I, were selected in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) by a novel nonnucleoside reverse transcriptase inhibitor (NNRTI). G112D is located...
7.
Samal J, Kelly S, Na-Shatal A, Elhakiem A, Das A, Ding M, et al.
JCI Insight
. 2018 Sep;
3(18).
PMID: 30232273
A major pathogenic feature associated with HIV infection is lymphoid fibrosis, which persists during antiretroviral therapy (ART). Lymphoid tissues play critical roles in the generation of antigen-specific immune response, and...
8.
Smith S, Pauly G, Akram A, Melody K, Ambrose Z, Schneider J, et al.
J Acquir Immune Defic Syndr
. 2016 Apr;
72(5):485-91.
PMID: 27124362
Background: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by Food and Drug Administration to combat HIV-1 infections. NNRTIs inhibit the chemical step in viral...
9.
Smith S, Pauly G, Akram A, Melody K, Rai G, Maloney D, et al.
Retrovirology
. 2016 Feb;
13:11.
PMID: 26880034
Background: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are a class of antiretroviral compounds that bind in an allosteric binding pocket in HIV-1 RT, located about 10 Å from the polymerase active...
10.
Melody K, McBeth S, Kline C, Kashuba A, Mellors J, Ambrose Z
Antimicrob Agents Chemother
. 2015 Oct;
59(12):7762-70.
PMID: 26438501
Preexposure prophylaxis (PrEP) using antiretroviral drugs is effective in reducing the risk of human immunodeficiency virus type 1 (HIV-1) infection, but adherence to the PrEP regimen is needed. To improve...